Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Inhibits
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics

Brand Names


Belgium: Myk I; Luxembourg: Myk 1; Netherlands: Myk 1.

North America

USA: Exelderm.

Latin America

Argentina: Antifungal.


Japan: Exelderm.

Drug combinations


Sulconazole Nitrate: C~18~H~15~Cl~3~N~2~S HNO~3~. Mw: 460.76. (1) 1H-Imidazole, 1-[2-[[(4-chlorophenyl)methyl]thio]-2-(2,4-dichlorophenyl)ethyl]-, mononitrate, (±)-; (2)(±)-1-[2,4-Dichloro-β-[(p-chlorobenzyl)thio]phenethyl]imidazole mononitrate. CAS-61318-91-0; CAS-61318-90-9 (sulconazole)(1977).

Pharmacologic Category

Antifungals; Azoles. Topical Antifungal Agent. (ATC-Code: D01AC09).

Mechanism of action

Imidazole-derivative azole antifungal. Usually fungistatic. May be fungicidal at high concentrations against very susceptible organisms. Alters cellular membranes, resulting in increased membrane permeability, secondary metabolic effects, and growth inhibition. Fungistatic activity may result from interference with ergosterol synthesis. Active in vitro against dermatophytes such as Epidermophyton floccosum, Microsporum audouinii, M. canis, M. gypseum, Trichophyton mentagrophytes, T. rubrum, T. tonsurans, and T. violaceum. Active in vitro against yeasts such as Candida albicans, C. glabrata (formerly Torulopsis glabrata), C. guilliermondii, C. krusei, C. parapsilosis, C. pseudotropicalis, and C. tropicalis. Active in vitro against other fungi such as Malassezia furfur (Pityrosporum orbiculare or P. ovale), Aspergillus, Blastomyces dermatitidis, Cryptococcus neoformans, Histoplasma capsulatum, and Paracoccidioides brasiliensis. Active in vitro against some Gram-positive bacteria such as Bacillus subtilis, Clostridium perfringens, C. tetani, C. botulinum, Enterococcus faecalis, Erysipelothrix rhusiopathiae, Micrococcus luteus, Propionibacterium acnes, Staphylococcus aureus, S. epidermidis, and S. saprophyticus. Cross-resistance can occur among azole antifungals. Some C. albicans isolates from patients undergoing long-term azole antifungal therapy show decreased in vitro susceptibility to sulconazole and other imidazole-derivative antifungals as well as to triazole derivatives.

Therapeutic use

Superficial fungal infections of skin (tinea cruris (jock itch), tinea corporis (ringworm), tinea versicolor, and possibly tinea pedis (athlete’s foot)).

Pregnancy and lactiation implications

Unknown whether distributed into milk. Caution advised.

Unlabeled use


Hypersensitivity to sulconazole or any component of the formulation.

Warnings and precautions

Discontinue if sensitivity or irritation occurs. For topical use only; avoid contact with eyes.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart